PTC Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
PTC Therapeutics (PTCT) Posts Smaller-than-Expected Q2 Loss on Much Higher Revs; Raises Outlook
August 8, 2017 4:51 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($0.44), $0.84 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $45.8 million versus the consensus estimate of $28.78 million.
2017 Guidance:
Translarna net sales for 2017 are now anticipated to be between $120 and $140 million,... More